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Abstract
Background: Live, attenuated measles virus (MeV) vaccine strains were generated by adaptation
to cell culture. The genetic basis for the attenuation of the vaccine strains is unknown. We
previously reported that adaptation of a pathogenic, wild-type MeV to Vero cells or primary
chicken embryo fibroblasts (CEFs) resulted in a loss of pathogenicity in rhesus macaques. The CEF-
adapted virus (D-CEF) contained single amino acid changes in the C and matrix (M) proteins and
two substitutions in the shared amino terminal domain of the phosphoprotein (P) and V protein.
The Vero-adapted virus (D-VI) had a mutation in the cytoplasmic tail of the hemagglutinin (H)
protein.
Results: In vitro assays were used to test the functions of the wild-type and mutant proteins. The
substitution in the C protein of D-CEF decreased its ability to inhibit mini-genome replication, while
the wild-type and mutant M proteins inhibited replication to the same extent. The substitution in
the cytoplasmic tail of the D-VI H protein resulted in reduced fusion in a quantitative fusion assay.
Co-expression of M proteins with wild-type fusion and H proteins decreased fusion activity, but
the mutation in the M protein of D-CEF did not affect this function. Both mutations in the P and V
proteins of D-CEF reduced the ability of these proteins to inhibit type I and II interferon signaling.
Conclusion: Adaptation of a wild-type MeV to cell culture selected for genetic changes that
caused measurable functional differences in viral proteins.
Background
The live attenuated vaccines currently used to protect
against infection by measles virus (MeV) were developed
well in advance of modern molecular biologic techniques,
and the genetic basis of the attenuation of these vaccine
strains remains a subject of investigation. The vaccines
were generated by extensive passaging in cell culture,
often involving cells or tissues of avian origin [1-4]. The
identification of genomic markers for the attenuation of
MeV would facilitate surveillance of wild-type MeVs by
providing a means to discriminate between wild-type
viruses and vaccine strains of the same genotype. In addi-
tion, this genetic information could be used to monitor
the safety and stability of new vaccine lots and could con-
tribute to the development of improved vaccines for MeV.
The complete genomic sequences of many vaccine strains
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have been published [5-7]; however, the wild-type pro-
genitors are no longer available for comparison or have
undergone passaging in cell culture [8]. We have
attempted to replicate the process of attenuation through
cell culture adaptation with a wild-type MeV that is path-
ogenic for rhesus macaques [9,10].
MeV is a member of the genus Morbillivirus of the family
Paramyxoviridae. Its monopartite, single-stranded, nega-
tive-sense RNA genome contains six genes, which encode
eight proteins (reviewed in [11]). The non-coding regions
of the termini contain the promoters for transcription and
replication and the encapsidation signals. The nucleopro-
tein (N, 60 kDa) encapsidates the viral genome and binds
the polymerase complex. The P gene encodes three pro-
teins, the phosphoprotein (P, 72 kDa) and the C (21 kDa)
and V (40 kDa) proteins. C is translated from an overlap-
ping reading frame while V shares an amino terminal
domain (NTD) of 231 amino acids with P, but has a
unique carboxyl terminus as a result of RNA editing [12].
P is a necessary component of the polymerase complex
and acts as a scaffolding protein in nucleocapsid assem-
bly. It also contributes to the inhibition of type I inter-
feron (IFN) signaling in infected cells [13]. The C and V
proteins regulate polymerase activity [14-17] and act as
inhibitors of IFN signaling [18-20]. The matrix protein
(M, 38 kDa) plays a role in viral assembly and in the trans-
port of viral glycoproteins to the apical membrane of
polarized cells [21]. It also affects virus-induced fusion in
cell culture [22,23]. The fusion (F) and hemagglutinin (H,
78 kDa) glycoproteins are expressed on the surface of
infected cells and of the virion. The F protein is a disulfide-
linked dimer (41 and 20 kDa) which promotes fusion
with adjacent membranes. The H protein binds to specific
receptors on the host cell and is a required co-factor for
fusion [24]. The Large protein (L, 200 kDa) acts as the cat-
alytic subunit of the polymerase complex.
In order to recreate the process of attenuation through cell
culture adaptation, the D87-wt virus, which is pathogenic
in rhesus macaques [10], was passaged in Vero cells, Vero/
hSLAM cells and primary chicken embryo fibroblasts
(CEFs) [9]. Vero cells (African green monkey kidney cells)
express a homologue of CD46 which serves as a receptor
for cell culture-adapted MeV strains [25-27]. Vero/hSLAM
cells express both CD46 and human SLAM (signaling
lymphocyte activation molecule), which is used as a
receptor by all MeV strains [28-31]. CEFs do not express
either of the two known receptors for MeV [32]. After nine
passages in Vero/hSLAM cells, the resulting virus stock, D-
V/S, remained genetically identical to D87-wt and
retained pathogenicity in rhesus macaques. The Vero cell-
adapted virus, D-VI, contained one amino acid substitu-
tion in the cytoplasmic tail of the H protein, while the
CEF-adapted virus, D-CEF, contained four amino acid
changes in the P, C, V and M proteins. Both viruses dem-
onstrated attenuation in rhesus macaques. None of the
viruses were able to infect Chinese hamster ovary cells
expressing the receptor CD46, indicating that they had
not adapted to use CD46 as a receptor [9]. The absence of
a change in receptor usage indicated that, in this case,
attenuation was a result of genetic changes affecting viral
maturation, replication or interaction of viral proteins
with intracellular host proteins.
In order to understand the consequences of the amino
acid substitutions found in D-VI and D-CEF for protein
functions,  in vitro assays were used to analyze specific
functions of the P, C, V, M and H proteins of the cell cul-
ture-adapted viruses. The effect of mutations in P, C, V
and M on viral replication was examined with mini-
genome replication assays. Quantitative fusion assays
were used to analyze the role of the substitutions in M and
H proteins in cell-cell fusion. The effect of the substitu-
tions in P, C and V on IFN signaling was analyzed with
reporter proteins expressed under the control of IFN-
inducible promoters.
Results
Transient expression of wild-type and mutant proteins
Adaptation of D87-wt to CEFs resulted in the introduction
of four amino acid changes, V102A in the C protein,
Y110H and V120A in the NTD of the P and V proteins,
and T84I in the M protein. Adaptation of D87-wt to Vero
cells introduced one amino acid substitution in the H pro-
tein, L30P [9]. The ORFs for all eight proteins expressed by
D87-wt as well as for the P, C, V and M proteins of D-CEF
and the H protein of D-VI were cloned into the expression
vector pTM1 behind a T7 promoter. The C ORF was
silenced in the plasmids encoding P and V clones without
affecting the amino acid sequence of the P and V proteins.
Radio-immunoprecipitations of transiently expressed
proteins demonstrated that all clones expressed proteins
of the expected molecular sizes (figure 1A, B, C). The D87-
wt L protein was co-expressed and co-immunoprecipi-
tated with D87-wt P, using an antiserum to P (figure 1A,
lanes 6–8). The M protein of D-CEF migrated at a slightly
lower apparent molecular weight than the wt M protein
(figure 1B, lanes 10, 11). Such differences in apparent
molecular weight have been reported previously for M
proteins of several MeV strains [33,34]. The P, C and V
ORFs of D-CEF and the P ORF of D87-wt were subcloned
into the mammalian expression vector pCAGGS to facili-
tate transcription by cellular RNA polymerases. Cloning
of the D87-wt C and V ORFs into pCAGGS was described
previously [35]. D87 V-110H and D87 V-120A each con-
tained one of the two mutations identified in the V pro-
tein of D-CEF. Expression of P, C, and V proteins from
pCAGGS was demonstrated by immunoprecipitation (fig-
ure 1D).Virology Journal 2008, 5:129 http://www.virologyj.com/content/5/1/129
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Activity of P, C, V and M proteins in mini-genome 
replication assays
A mini-genome replication assay was used to analyze the
ability of D87-wt P and D-CEF P to support polymerase
activity. In this and all subsequent experiments, the N and
L proteins were derived from D87-wt. As expected, both
D87-wt P and D-CEF P supported replication equally well
(figure 2A). In all subsequent replication assays, the D87-
wt P protein was used.
The C and V proteins of different strains of MeV inhibit
mini-genome replication to varying degrees [14,15,36].
The D87-wt C protein reduced CAT protein production by
89%, while the D-CEF C protein inhibited CAT produc-
tion by only 31% (figure 2B). D87-wt V and D-CEF V
reduced CAT protein production by 68% and 72%,
respectively (figure 2C). These results demonstrate that
the two amino acid substitutions in the NTDs of the P and
V proteins of D-CEF did not affect the function of either
protein in the mini-genome replication assay. In contrast,
the single amino acid difference between the C proteins of
the wild-type and the cell culture-adapted virus lead to a
significant difference in their ability to inhibit replication.
Previous reports showed that the M protein of MeV can
inhibit polymerase activity [34,37]. We have confirmed
that co-expression of the M protein in the mini-genome
replication assay leads to a reduction in reporter protein
levels in a dose-dependent manner (figure 3A). Figure 3B
demonstrates that both D87-wt M and D-CEF M reduced
CAT protein production by 45%, indicating that the single
amino acid substitution in D-CEF M did not affect the
level of inhibition.
Activity of H and M proteins in quantitative fusion assays
Mutations in the cytoplasmic tails of the F and H proteins
can affect fusion [38-40]. A quantitative fusion assay with
transiently expressed F and H proteins was used to meas-
Expression of proteins derived from D87-wt, D-VI and D-CEF Figure 1
Expression of proteins derived from D87-wt, D-VI and D-CEF. (A, B, C) A549 cells were infected with vTF7-3 and 
transfected with the indicated pTM1-derived plasmids. (D) Vero cells were transfected with the indicated pCAGGS-derived 
plasmids. In all cases, proteins were labeled with 35S-methionine, precipitated with protein-specific antisera and separated by 
SDS-PAGE. Molecular mass markers (kDa) are shown on the left in each panel, the positions of proteins are indicated on the 
right.
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Effect of mutations in the P, C and V proteins of MeV on mini-genome replication Figure 2
Effect of mutations in the P, C and V proteins of MeV on mini-genome replication. (A) CV-1 cells were infected 
with MVAT7 and transfected with pMV107(-)CAT, pTM1-D87-wt N, pTM1-D87-wt L and the indicated plasmids expressing P 
proteins. (B, C) CV-1 cells were infected with MVAT7 and transfected with pMV107(-)CAT, pTM1-D87-wt N, pTM1-D87-wt 
P, pTM1-D87-wt L and 1 μg of the indicated plasmids. For the negative controls, pTM1-D87-wt L was omitted. The amount of 
transfected DNA was kept constant through the addition of pTM1 vector. CAT protein production in cytoplasmic extracts of 
quadruplicate samples was measured by ELISA. The amount of CAT protein measured in the presence of pTM1-D87-wt P and 
absence of C- or V-expressing plasmids was set to 100% in each panel. Each panel shows the average of three independent 
experiments. Error bars denote one standard deviation. (*: P ≤ 0.01, **: P ≤ 0.001)
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ure the extent of fusion support provided by the H pro-
teins of D87-wt and D-VI. Co-expression of D-VI H
instead of D87-wt H resulted in an 82% reduction in
reporter protein activity (figure 4A). Radioimmunopre-
cipitation experiments demonstrated that both H proteins
were expressed equally well on the surface of transfected
cells (data not shown).
Co-expression of M proteins with F and H proteins can
modulate fusion activity, both in in vitro assays and in the
intact virus [22,23]. Co-expression of wild-type or D-CEF
M proteins reduced fusion significantly compared to the
expression of F and H alone (figure 4B). The M proteins of
D87-wt and D-CEF inhibited fusion by 56% and 57%,
respectively, demonstrating that there was no difference in
inhibition between the two M variants. These results
showed that the amino acid substitution in M did not
affect fusion inhibition, while a single amino acid substi-
tution in the cytoplasmic tail of D-VI H had a significant
effect on the H protein's ability to support fusion.
Effect of P, C, and V proteins on IFN-β signaling
The ability of D87-wt V and C to inhibit IFN signaling was
described previously [35]. In this report, the P, C, and V
proteins of D87-wt and D-CEF were compared in their
ability to reduce the expression of an IFN-β-responsive
reporter gene. D87-wt P inhibited luciferase expression by
27%, while D-CEF P lost the ability to inhibit IFN-β sign-
aling (figure 5A). D87-wt C and D-CEF C reduced IFN-β
signaling by 37% and 23%, respectively (figure 5B). D87-
wt V and D-CEF V decreased reporter protein expression
by 93% (14.7 fold) and 71% (3.4 fold), respectively (fig-
ure 5C). The V protein of D87-wt was modified to contain
the amino acid substitution Y110H or V120A found in D-
CEF V, and these mutant V proteins demonstrated inter-
mediate levels of inhibition (figure 5C). Our results show
that all three wild-type proteins inhibited IFN-β signaling
more effectively than did the corresponding protein from
D-CEF. The most potent inhibitor of signaling was the V
protein, followed by C and P. Both mutations in the NTD
of D-CEF V contributed to its reduced ability to inhibit
IFN-β signaling, but even with both mutations, D-CEF V
still retained significant inhibitory potential.
Effect of P and V proteins on IFN-γ signaling
The P and V proteins of D87-wt and D-CEF were com-
pared in their ability to inhibit the expression of an IFN-γ-
responsive reporter gene. We reported previously that the
C protein of MeV does not inhibit IFN-γ signaling [35]. As
expected, neither the C protein of D87-wt nor that of D-
CEF inhibited the expression of an IFN-γ-responsive
reporter gene (data not shown). D87-wt P reduced luci-
ferase expression by 28%, while D-CEF P did not inhibit
IFN-γ signaling (figure 6A). D87-wt V reduced IFN-γ sign-
aling by 78%, while D-CEF V lost the ability to inhibit
reporter gene expression (figure 6B). Each of the two
mutants containing one or the other of the amino acid
substitutions of D-CEF V failed to inhibit IFN-γ signaling.
These results showed that the P and V proteins of D87-wt
inhibited IFN-γ signaling more effectively than did the
corresponding proteins from D-CEF and that V was a
more potent inhibitor than P. Each of the substitutions
found in the V protein of D-CEF individually caused a
complete loss of this activity.
Discussion
The C protein of D-CEF demonstrated a significantly
reduced ability to inhibit reporter protein expression in a
mini-genome replication assay. We previously showed
that naturally occurring substitutions between amino
acids 45 and 167 of the MeV C protein modified its ability
to regulate polymerase activity [14]. Therefore, the single
amino acid substitution (V102A) of the D-CEF C protein
The M protein of MeV inhibits mini-genome replication Figure 3
The M protein of MeV inhibits mini-genome replica-
tion. (A) CV-1 cells were infected with MVAT7 and trans-
fected with pMV107(-)CAT, pTM1-D87-wt N, pTM1-D87-wt 
P, pTM1-D87-wt L and increasing amounts of pTM1-D87-wt 
M. (B) CV-1 cells were infected with MVAT7 and transfected 
with pMV107(-)CAT, pTM1-D87-wt N, pTM1-D87-wt P, 
pTM1-D87-wt L and 2 μg of the indicated plasmids. Transfec-
tions and ELISA were performed as described in the legend 
to figure 1. (*: P ≤ 0.01)
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lies within a domain of the C protein that regulates repli-
cation. Recombinant MeVs defective in expression of the
C protein induce more IFN than wild-type viruses, indi-
cating that the increased production of RNA may activate
cellular RNA sensors [41]. However, it is still unclear
which effect mutations in this domain have on attenua-
tion. In addition to regulating polymerase activity, the C
protein participates in the inhibition of the host IFN
response and cell death and acts as an infectivity factor
that improves particle release [19,35,42,43]. Since the
MeV C protein is a multifunctional protein, it is difficult
to separate the effects that amino acid substitutions have
on each of its activities; however, in vitro assays are useful
tools to measure individual functions.
Effect of mutations in the H and M proteins of MeV on quantitative fusion Figure 4
Effect of mutations in the H and M proteins of MeV on quantitative fusion. (A) fusion produced by H and F proteins, 
(B) inhibition of fusion by co-expressed M protein. Vero/hSLAM cells were infected with MVAT7 and transfected with the indi-
cated plasmids. The amount of transfected DNA was kept constant through the addition of pTM1 vector. β-galactosidase pro-
tein production in cytoplasmic extracts of quadruplicate samples was measured as described in the Methods section. The 
amount of β-galactosidase protein measured in the wells transfected with pTM1-D87-wt F and pTM1-D87-wt H was set to 
100% in each panel. Each panel shows the average of three independent experiments. Error bars denote one standard devia-
tion. In panels (A) and (B) F indicates D87-wt F, in panel (B), H indicates D87-wt H. (**: P ≤ 0.001)
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Figure 5 (see legend on next page)
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The V protein of MeV has been shown to regulate replica-
tion both in mini-genome assays and in infected cells
[16,36]. Mutational analysis characterized two domains
involved in inhibition of mini-genome replication, amino
acids 113 and 114 in the NTD and amino acids 238–278
in the unique carboxyl terminus [17,36]. Amino acids
110–131 are highly conserved among morbilliviruses
[17]. Despite the proximity of the mutations found in D-
CEF V (amino acids 110 and 120) to this conserved region
of V and P, these substitutions had no effect on reporter
protein production in the mini genome replication assay.
The M protein of MeV inhibited in vitro transcription of
purified nucleocapsids, and M proteins of different MeVs
varied in their ability to inhibit in vitro transcription [34].
SiRNAs directed against the M gene increased replication,
transcription and protein expression of other structural
proteins [37]. A dose-dependent inhibition of reporter
protein production in the mini-genome replication assay
confirmed the earlier findings that M inhibits transcrip-
tion and/or replication. However, there was no difference
in the level of inhibition between the wild-type and
mutant M proteins. Since both M proteins inhibited
fusion to the same extent, the role of the mutation in D-
CEF M remains unknown. While three of the four amino
acid substitutions in D-CEF resulted in functional differ-
ences in the in vitro assays, it will be necessary to create a
recombinant virus containing only the mutation in M to
measure its effect on viral replication.
The L30P substitution in the cytoplasmic tail of the D-VI
H protein increased titers of extracellular virus in Vero
cells [9]. In this report, we demonstrated that the substitu-
tion led to a significant reduction in fusion help in Vero/
hSLAM cells. Since neither D-V/S nor D-VI induced fusion
in Vero cells (data not shown), the alteration in fusion
measured in Vero/hSLAM cells probably does not indicate
that fusion capacity itself played a role in cell culture
adaptation. However, alterations in the cytoplasmic tails
of MeV glycoproteins can modulate the interaction of F
and H proteins, which affects fusion [38-40]. We hypoth-
esize that decreased fusion indicates a stronger interaction
between F and H proteins, which may affect titers. An
alternative interpretation of our data is based on the
observation that expression of MeV glycoproteins and/or
M leads to the formation of virus-like particles (VLPs)
Cell culture adaptation affects the inhibition of IFN-β signaling by the P, C, and V proteins of MeV Figure 5 (see previous page)
Cell culture adaptation affects the inhibition of IFN-β signaling by the P, C, and V proteins of MeV. Vero cells 
were transfected with a plasmid constitutively expressing renilla luciferase, a plasmid expressing firefly luciferase under the con-
trol of an IFN-α/β-responsive promoter and the plasmids as indicated in the three panels. Forty-eight hours after transfection, 
cells were stimulated with IFN-β for six hours, lysed and tested for luciferase activity. VC-indicates cells transfected with 
pCAGGS empty vector but not stimulated while VC+ indicates cells transfected with pCAGGS empty vector and stimulated 
with IFN-β. Results are expressed as a ratio of firefly to renilla luciferase luminescence taken as a percentage of the lumines-
cence obtained using IFN-stimulated, empty pCAGGS vector (VC+). (A) results of IFN-β signaling assay with P proteins from 
D87-wt and D-CEF, (B, C) inhibition of IFN-β signaling by the C and V proteins, respectively. The data shown are an average of 
three experiments done with triplicate samples. Error bars denote one standard deviation. Bars marked with a are significantly 
different from VC+ with a P ≤ 0.05. (*: P ≤ 0.01, **: P ≤ 0.001)
Cell culture adaptation affects the inhibition of IFN-γ signaling  by the P and V proteins of MeV Figure 6
Cell culture adaptation affects the inhibition of IFN-γ 
signaling by the P and V proteins of MeV. Experiments 
were performed as described in the legend to figure 5, 
except that a reporter plasmid expressing firefly luciferase 
under the control of an IFN-γ-responsive promoter and IFN-
γ were used for stimulation. (A) results of IFN-γ signaling 
assays with P proteins from D87-wt and D-CEF, (B) inhibi-
tion of IFN-γ signaling by the V proteins. Bars marked with a 
are significantly different from VC+ with a P ≤ 0.05. (**: P ≤ 
0.001)
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[44]. A decrease in fusion may be the result of increased
budding, reducing the amount of available F and H on the
surface of the effector cells. VLPs could also interact with
the indicator cells in the fusion assay, acting as soluble
inhibitors of fusion.
In this first report to directly compare the ability of the P,
C, and V proteins of MeV to inhibit both IFN-β and IFN-γ
signaling, the V protein was clearly the most potent inhib-
itor of both signaling pathways. Although the P protein of
MeV has been previously shown to inhibit the expression
of an IFN-α/β-responsive reporter gene [13], we did not
find the P protein of D87-wt to be as strong an inhibitor
of either IFN-β or IFN-γ signaling as the previous report
indicated. This discrepancy may be due to the different
cell types used in each study. Amino acid 110 in the NTD
of the P and V proteins plays a critical role in the ability of
MeV to inhibit IFN signaling [13,35,45], but this is the
first report to demonstrate the contribution of amino acid
residue 120 to this activity. Amino acids 110–131 are
highly conserved among morbilliviruses [17] and bind
STAT1 [46], which explains why the shared NTD inhibits
both type I and type II IFN signaling. The unique carboxyl
terminal domain of V binds STAT2 [46], suggesting that it
can only inhibit type I IFN signaling. Our findings, com-
bined with those of previous publications [13,45-47], are
summarized in a model of the STAT-binding sites in the P
and V proteins and the resulting IFN-signaling inhibition
(figure 7).
Expression of P or V mutants that did not inhibit IFN sig-
naling lead to reproducible apparent augmentation of
reporter protein expression above the level of the positive
control (figures 5A, 6). The mechanism behind this phe-
nomenon is unclear. Yokota et al. [20] reported that the
inducibility of an IFN-γ-responsive reporter gene was
enhanced in MeV-infected CaSki (epitheloid carcinoma)
cells compared to uninfected cells. Furthermore, treat-
ment with IFN-γ caused a prolonged and enhanced phos-
phorylation of Jak1 and Jak2 in these MeV-infected cells
[20]. The authors hypothesized that the enhanced phos-
phorylation may be the reason for increased reporter gene
expression. It is unknown whether a similar enhanced
phosphorylation of Jak proteins may also occur in plas-
mid-transfected cells expressing MeV proteins. Interaction
of P or V with other cellular proteins, perhaps other IFN-
inducible genes, may contribute to this effect.
We are faced with the paradox that adaptation to a pre-
sumably IFN-competent primary cell line such as CEFs
induced a loss of the ability to counteract IFN signaling.
Our hypothesis is that CEF adaptation induces substitu-
tions that improve the interaction of viral proteins with
avian proteins, perhaps even proteins involved in avian
IFN signaling. IFN signaling inhibition by paramyxovi-
ruses can be species specific, for example PIV5 cannot
inhibit IFN-α/β signaling in murine cell lines [48]. Similar
species specific adaptation may be a cause for the attenu-
ation of MeV vaccine strains, many of which have been
passaged extensively in avian cells or tissues [8]. Since the
reduced ability to inhibit IFN signaling would presumably
not affect the replication of D-CEF in Vero cells, the
observed improvement in viral titers compared to D-V/S
may be the result of the mutations in the C and M pro-
teins. The construction of recombinant viruses expressing
individual mutations identified in D-CEF will make it
possible to examine the role of each substitution sepa-
rately.
A number of studies have identified amino acid substitu-
tions in most proteins of MeV [9,49,50] as a result of cell
culture adaptation. A comparison of the sequences of five
vaccine strains derived from the Edmonston progenitor
with the Edmonston wt strain identified amino acid dif-
ferences in every protein [6]. Replacement of ORFs in a
recombinant wild-type MeV with ORFs from an attenu-
ated virus demonstrated that multiple proteins contrib-
uted to cell culture adaptation [51,52]. It is likely that
there are several pathways to attenuation and amino acid
substitutions in multiple proteins may have a cumulative
effect on pathogenicity.
Conclusion
Adaptation of a wild-type MeV to Vero cells and CEFs
selected for genetic changes that caused measurable func-
tional differences in viral proteins. Our results demon-
strate the usefulness of in vitro assays to characterize the
consequences of cell culture adaptation. Identification of
Location of IFN-inhibiting domains in the P and V proteins of  MeV Figure 7
Location of IFN-inhibiting domains in the P and V 
proteins of MeV. P indicates P protein, V indicates V pro-
tein, NTD indicates shared amino terminal domain, and CTD 
indicates unique carboxyl terminal domain. The black bars 
denote the domain from amino acids 110–130 in the NTD. 
Positions of important amino acids are marked.
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mutations that are associated with the alteration of pro-
tein function will increase our understanding of the path-
ogenicity of MeV. This knowledge can be used towards
engineering recombinant strains of MeV that can be used
therapeutically, such as oncolytic viruses, as well as
towards the development of improved MeV vaccines.
Methods
Cells and viruses
A549, Vero, CV-1 and Vero/hSLAM cells [30] were main-
tained in Dulbecco's modified Eagle's medium supple-
mented with 10% fetal calf serum, glutamine and
antibiotics. G418 sulfate (Cellgro) was used to maintain
expression of hSLAM in Vero/hSLAM cells (0.4 mg ml-1).
The MVAT7 and vTF7-3 recombinant vaccinia viruses
were provided by B. Moss, Bethesda, MD, USA and were
propagated in CEFs and Vero cells, respectively.
Derivation of plasmids
The cloning of the C and V open reading frames (ORFs) of
D87-wt has been described [35]. The same RNA prepara-
tions that were used for sequence analysis of D87-wt, D-
CEF and D-VI [9] were used to derive cDNA for the N, P,
M, F, H and L ORFs of D87-wt, the P, C, V and M ORFs of
D-CEF and the H ORF of D-VI. Reverse transcriptase reac-
tions were performed with an oligo (dT) primer and
Superscript II reverse transcriptase (Invitrogen). PCR was
performed with the Elongase enzyme mix (Invitrogen)
using gene-specific primers. Primer sequences are availa-
ble upon request. The start codon of the C protein was
mutated in the P/V forward primer (ATG changed to
ACG); the substitution is silent in P and V. The L gene was
amplified in two fragments that overlapped at a unique
NheI site (nt 12216). The genes were cloned into the
expression vector pTM1 by using the following restriction
sites: SacI and SpeI (N), EcoRI and SpeI (P, C, V), SpeI and
PstI (M), SacI and XhoI (F), BamHI and EcoRI (H),
BamHI and SalI (L). The mammalian expression vector,
pCAGGS [53] was provided by C. Basler, Mount Sinai
School of Medicine, New York, NY, USA. Restriction sites
EcoRI and XhoI were used to subclone the P, C and V
ORFs into pCAGGS, to which a linker containing EcoRI
and XhoI recognition sites had been added. D87-V-120A
and D87-V-110H were generated from D-CEF V by using
a three-step PCR method with the P gene-specific primers
and primers containing the desired mutation (under-
lined), V110F (5'-GCA CTG GGC TAC AGT GCT ATC ATG
TTT ATG ATC ACA GCG G-3'), V110R (5'-CCG CTG TGA
TCA TAA ACA TGA TAG CAC TGT AGC CCA GTG C-3'),
V120F (5'-GCG GTG AAG CGG TTA AGG GAA TCC AAG-
3'), V120R (5'-CTT GGA TTC CCT TAA CCG CTT CAC
CGC-3'). The mutated amplicons were cloned into the
pCAGGS vector using EcoRI  and  XhoI. All clones were
sequenced using the ABI PRISM Dye Terminator Reaction
Kit and the ABI 3100 and 3130xL Genetic Analyzer
machines (Perkin Elmer-Applied Biosystems). Sequence
data were analyzed with the Sequencher™ DNA sequenc-
ing program (Gene Codes Corporation) and confirmed by
comparison to the published sequence for each strain. The
mini-genome construct, pMV107(-)CAT [54], was a gift of
M. Billeter (Zürich, Switzerland). pG1NT7, which carries
the lac Z gene under control of the T7 promoter, was pro-
vided by B. Fredericksen, University of Maryland, MD,
USA. The pISRE and pGAS plasmids were provided by R.E.
Randall, North Haugh University of St. Andrews, Fife,
Scotland. The pRL-TK plasmid was part of the Dual
Reporter Luciferase System (Promega).
Protein expression
For expression of genes cloned into pTM1, A549 cells in 6-
well plates were infected with vTF7-3 at a multiplicity of
infection (MOI) of 5 and transfected 45 min later. 2 μg
plasmid DNA in Opti-MEM medium (Invitrogen) were
transfected with Cellfectin (Invitrogen). pTM1 without a
coding sequence was used as a negative control. Cells were
starved for one hour in methionine-free medium (ICN),
followed by labeling with 35S-methionine for one hour
(N, P, C, V proteins) or four hours (L protein). For expres-
sion of M, F and H proteins, cells were labeled overnight
in the presence of 1% FBS. Cytoplasmic cell extracts were
prepared in NET-BSA buffer (150 mM NaCl, 5 mM EDTA,
50 mM Tris-HCl, 0.5% NP-40, 1 mg ml-1 BSA, pH 7.4).
Aliquots of cell extracts were incubated with protein-spe-
cific antisera (N, P, C, V, F, H) or monoclonal antibodies
(M) followed by precipitation with GammaBind G-
Sepharose (Amersham). The L protein was co-expressed
with the P protein and co-precipitated with P specific
antiserum. The complexes were separated on a 4–20%
gradient SDS-polyacrylamide gel (Bio-Rad Laboratories)
(N, P, C, V, L proteins) or a 10% SDS-polyacrylamide gel
(Bio-Rad Laboratories) (M, F, H proteins). Bands were vis-
ualized by autoradiography. Expression of genes cloned
into pCAGGS was performed as described previously,
using the same antisera as described above [35].
Replication assay
Mini-genome replication assays were performed as
described previously [14]. In experiments including
pTM1-C, -V or -M plasmids, transfected amounts are listed
in the figures. CAT protein concentrations measured in
cell extracts of cells transfected with wild-type N, P, L plas-
mids were set to 100%.
Fusion assay
Vero/hSLAM cells in 12-well plates (effector cells) were
infected with MVAT7 at an MOI of 5 and transfected with
10 ng pTM1-D87 F, 20 ng plasmid expressing H and/or 10
ng plasmid expressing M in Opti-MEM (Invitrogen) using
Cellfectin (Invitrogen). pTM1 vector alone, or H, F or M
expressing plasmids alone were transfected as negativeVirology Journal 2008, 5:129 http://www.virologyj.com/content/5/1/129
Page 11 of 12
(page number not for citation purposes)
controls. The amount of transfected DNA was kept con-
stant through the addition of pTM1 vector. For every pro-
tein tested, two plasmid preparations were used, and for
every sample, transfection mixtures were tested in dupli-
cate. A second set of Vero/hSLAM cells in 6-well plates
(indicator cells) was transfected with 3 μg pG1NT7 using
TransIT-LT1 (Mirus Bio). 18 hours after transfection, indi-
cator cells were detached with trypsin (Invitrogen) and
added to the wells containing the effector cells. 4 to 5
hours later, expression of β-galactosidase in cytoplasmic
extracts was measured with a luminescent substrate
(Clontech), following the manufacturer's Alternate Cell
Lysis Protocol. A Fluoroscan Ascent microplate luminom-
eter (Thermo Electron) was used to measure lumines-
cence. Purified β-galactosidase (Clontech) was used to
establish a standard curve. β-galactosidase concentrations
measured in lysates of cells transfected with wild-type F
and H plasmids were set to 100%.
IFN-responsive reporter gene assay
Experiments were carried out as described previously [35].
Briefly, Vero cells in 24-well plates were transfected with
Opti-MEM medium (Invitrogen) and TransIT-LT1 (Mirus
Bio). 0.9 μg pISRE and 0.1 μg pRL-tk or 0.7 μg pGAS and
0.3 μg pRL-tk were co-transfected with 1 μg of pCAGGS-P,
-C, or -V plasmid DNA. 48 hours after transfection, cells
were treated with 100 U rhIFN-β (Biosource Interna-
tional) for six hours and cell lysates were harvested for
detection of luciferase activity using the Dual Reporter
Luciferase System (Promega). Luminescence obtained
using IFN-stimulated, pCAGGS-transfected cells was set to
100%.
Statistical analysis
For two group comparisons, a two-tailed Student's t-test
was used, and a value of p < 0.05 was considered statisti-
cally significant.
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